Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Histologically confirmed recurrent or metastatic colorectal cancer
- Measurable disease per RECIST v1.1
- Microsatellite instability expression detected by an accredited laboratory
- Participants enrolled into the C3 Cohort must have not had treatment for their
metastatic disease
Exclusion Criteria:
- Active brain metastases or leptomeningeal metastases are not allowed
- Prior treatment with an anti-Programmed Death Receptor (PD)-1, anti-PD-L1, anti-PD-L2,
anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other antibody or
drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
- Prior malignancy active within the previous 3 years except for locally curable cancers
- Participants with active, known or suspected autoimmune disease
- Participants with a condition requiring systemic treatment with either corticosteroids
or other immunosuppressive medications within 14 days of study drug administration
Other protocol-defined inclusion/exclusion criteria apply
Active, Not Recruiting
